Verastem, Inc. Files 8-K Report
Ticker: VSTM · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1526119
| Field | Detail |
|---|---|
| Company | Verastem, INC. (VSTM) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: VERA
TL;DR
VERA filed an 8-K, likely with financial updates. Check for details.
AI Summary
On August 13, 2025, Verastem, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates Verastem, Inc. is providing updated information to the SEC, which could include financial data or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- Verastem, Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- 117 Kendrick Street, Suite 500, Needham, MA 02494 (address) — Principal Executive Offices
- 001-35403 (company_id) — Commission File Number
FAQ
What specific financial statements or exhibits were filed with this 8-K?
The provided text indicates that 'Financial Statements and Exhibits' are part of the filing, but does not list the specific documents.
What 'Other Events' are being reported by Verastem, Inc. in this 8-K?
The filing is categorized under 'Other Events,' but the nature of these events is not detailed in the provided text.
What is the purpose of the 'Regulation FD Disclosure' mentioned in the filing?
The filing includes a 'Regulation FD Disclosure,' which typically relates to the non-exclusionary disclosure of material non-public information to all investors.
When was Verastem, Inc. incorporated and in which state?
Verastem, Inc. was incorporated in Delaware.
What is Verastem, Inc.'s primary business according to the SIC code?
Verastem, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2025-08-13 17:20:21
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share VSTM The Nasdaq
Filing Documents
- tm2523452d1_8k.htm (8-K) — 28KB
- tm2523452d1_ex99-1.htm (EX-99.1) — 18KB
- 0001104659-25-077659.txt ( ) — 215KB
- vstm-20250813.xsd (EX-101.SCH) — 3KB
- vstm-20250813_lab.xml (EX-101.LAB) — 33KB
- vstm-20250813_pre.xml (EX-101.PRE) — 22KB
- tm2523452d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On August 13, 2025, Verastem, Inc. (the "Company") issued a press release announcing updated safety and efficacy data from the GFH375 (known as VS-7375 in the U.S.) ("VS-7375") Phase 1/2 study in patients with advanced KRAS G12D mutant solid tumors conducted in China by the Company's partner, GenFleet Therapeutics ("GenFleet"). It is expected that the data will be presented in a mini oral presentation at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer between September 6-9, in Barcelona, Spain. A copy of this press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K.
01 Other Events
Item 8.01 Other Events Recent Developments Updated Data from VS-7375 Phase 1/A Study in Advanced KRAS G12D Mutant Solid Tumors GenFleet reported cumulative safety data across the entire study population and preliminary efficacy data specific to patients with advanced non-small cell lung cancer ("NSCLC") from the Phase 1/2 study in China. The study population includes 142 patients, including 28 with advanced NSCLC, 85 with advanced pancreatic ductal adenocarcinoma ("PDAC") and 29 with other solid tumors. As of the data cutoff of July 15, 2025, the median follow-up time was 4.5 (range: 1.8-12.2) months. Tumor response was observed across the dose range tested. Amongst the patients with NSCLC, all had metastatic disease at baseline, 64.3% had received at least two prior lines of systemic therapies, and 96.4% had received an anti-PD1/PD-L1 therapy. At the recommended Phase 2 dose of 600 mg once daily, the overall response rate ("ORR") was 68.8% (11/16) (both confirmed and unconfirmed) and the disease control rate ("DCR") was 93.8% (15/16). Among the 26 evaluable patients with NSCLC treated across all dose levels, the ORR was 57.7% (15/26) (both confirmed and unconfirmed) and the DCR was 88.5% (23/26). Across all cancer types and dose levels evaluated, the most common treatment-related adverse events ("TRAEs") occurring in at least 20% of patients were diarrhea, vomiting, nausea, anemia, decreased appetite, neutrophil count decreased, white blood cell count decreased, aspartate aminotransferase increased, asthenia, hypoalbuminemia, and alanine aminotransferase increased, predominately Grade 1 or 2 in severity. TRAEs and severe adverse events, greater than Grade 3, occurred in 27.5% (39/142) and 7.7% (11/142) of patients, respectively. Of the 142 patients in the safety population, 11 patients had dose reduction, and six discontinued due to TRAEs. No TRAE-related deaths were reported. VS-7375 is the lead program from the Verastem Oncology discovery and development
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated August 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERASTEM, INC. Dated: August 13, 2025 By: /s/ Daniel W. Paterson Daniel W. Paterson Chief Executive Officer